학술논문
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial
Document Type
Article
Author
Source
In The Lancet Haematology March 2018 5(3):e117-e126
Subject
Language
ISSN
2352-3026